Bionano Genomics (BNGO) Notes Payables (2023 - 2026)

Bionano Genomics' Notes Payables history runs 4 years deep, the most recent figure standing at $10.2 million for Q1 2026.

• In Q1 2026, Notes Payables fell 22.15% year-over-year to $10.2 million; the TTM figure through Mar 2026 stood at $10.2 million (down 22.15% YoY), while the FY2025 annual figure was $10.0 million, down 50.99% from the prior year.
• Notes Payables came in at $10.2 million for Q1 2026 at Bionano Genomics, up from $10.0 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $69.8 million in Q4 2023 to a low of $9.8 million in Q3 2025.
• A 4-year average of $20.8 million and a median of $14.0 million in 2024 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables tumbled 70.83% in 2024 and slipped 22.15% in 2026, its largest moves.
• Bionano Genomics' Notes Payables stood at $69.8 million in 2023, then sank by 70.83% to $20.4 million in 2024, then slumped by 50.99% to $10.0 million in 2025, then climbed by 1.73% to $10.2 million in 2026.
• According to Business Quant data, Notes Payables over the past three periods registered $10.2 million, $10.0 million, and $9.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison